Welcome to KentuckyLifeScience.com

This network addresses the growing informational and service needs of companies, patients, educators and others in their respective states while providing clients the opportunity to cost effectively advertise their job openings, events, facility availability and other services at the state level, regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting services.

Learn About Kentucky's BioHistory

Through Kentucky BioHistory, you can learn about the scientists, institutions, political leaders, and significant events that have shaped and are still shaping the biotechnology, medical device and life science industries in the state of Kentucky.

Local News...

Free News Release Posting & Archiving Service


• Stereotaxis' market leadership highlighted at Heart Rhythm 2008  Stereotaxis announced that its participation at Heart Rhythm 2008 reflects the broad market leadership it has achieved as the only provider of fully automated, remote navigation technology for cardiac ablation.
  Stereotaxis, Inc.  May 09, 2008  
  
  
• Spectrum announces sale of injectable generic drugs to Sagent  Spectrum Pharmaceuticals announced that it has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.
  Spectrum Pharmaceuticals, Inc.  May 09, 2008  
  
  
• Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye  Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
  Bayer  May 08, 2008  
  
  
• AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder  AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
  AstraZeneca  May 08, 2008  
  
  
• POZEN reports first quarter 2008 results  POZEN announced results for the first quarter ended March 31, 2008. POZEN reported a net loss of ($7.4) million, or ($0.25) per share on a diluted basis, for the first quarter of 2008, compared to a net loss of ($2.1) million, or ($0.07) per share on a diluted basis, for the first quarter of 2007.
  POZEN Inc.  May 08, 2008  
  
  

More... | Submit News Release | National News

New Job Postings...

Free Job Posting Trial Offer

• Associate Medical Director, Device Safety Allen Thomas Associates, Inc. (NJ)
• Preclinical Study Coordinator I, II, III SNBL USA, Ltd. (WA)
• Quality Assurance Analytical Auditor SNBL USA, Ltd. (WA)
• Senior Scientist/Senior Study Director, General Tox SNBL USA, Ltd. (WA)
• Medical Director Omeros Corporation (WA)

More... | Job Advertising... | About Job Postings...

Upcoming Events...

Free Event Posting Service

• 05/12/2008: World Pharmaceutical Congress
• 05/12/2008: Advertising, Promotion and Labeling Conference
• 05/12/2008: Generic, Supergenerics & Patent Strategies
• 05/13/2008: 2008 Healthcare Investor & Corporate Development Conference
• 05/13/2008: Recruiting 2008 Conference & Expo

More... | Submit Event | Event Advertising...